<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Red blood cell transfusion in infants and children: Indications</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Red blood cell transfusion in infants and children: Indications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Red blood cell transfusion in infants and children: Indications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jun Teruya, MD, DSc</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Aaron Tobian, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrienne G Randolph, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Transfusion of red blood cells (RBCs) can be lifesaving in patients with severe blood loss or severe chronic anemia. However, RBC transfusion has risks, including volume overload, transmission of infectious agents, transfusion reactions, and various immunologic consequences (including graft-versus-host disease).</p><p>The indications for RBC transfusion in infants and children will be reviewed here. Other aspects of transfusion in infants and children are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5935.html" rel="external">"Red blood cell transfusion in infants and children: Selection of blood products"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5938.html" rel="external">"Red blood cell transfusion in infants and children: Administration and complications"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7953.html" rel="external">"Pretransfusion testing for red blood cell transfusion"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PREVALENCE OF PEDIATRIC RED BLOOD CELL TRANSFUSION</span><span class="headingEndMark"> — </span>Approximately 1 to 3 percent of hospitalized children receive RBC transfusions [<a href="#rid1">1,2</a>].</p><p>In a study analyzing data on &gt;1,000,000 non-neonatal pediatric admissions from the 2016 Kid's Inpatient Database, RBC transfusions were administered in 2.6 percent [<a href="#rid2">2</a>]. RBC transfusion was more common in elective admissions compared with nonelective (presumably because elective admissions more often were surgical patients). RBC transfusion correlated with severity of illness, hospital length of stay, and risk of mortality.</p><p class="headingAnchor" id="H3"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H2306347856"><span class="h2">Rationale for transfusion</span><span class="headingEndMark"> — </span>Optimal transfusion practice is aimed at ensuring sufficient circulating RBCs to prevent or reduce morbidity and mortality associated with anemia while avoiding unnecessary transfusions. The principal rationale behind RBC transfusion is to provide sufficient cells to prevent or reverse tissue hypoxia due to limited oxygen delivery. There are limited data on the hemoglobin [Hgb] level required for sufficient tissue oxygenation in healthy children, but data from animal studies and clinical observations of children with chronic hemolytic anemia suggest that a hematocrit of 20 percent (which corresponds to a Hgb of approximately 6.7 g/dL) can generally be tolerated without adverse consequences [<a href="#rid3">3,4</a>]. The risk of mortality and other adverse outcomes increases with Hgb levels &lt;5 g/dL (hematocrit &lt;15 percent) [<a href="#rid5">5,6</a>].</p><p class="headingAnchor" id="H1835950455"><span class="h2">Restrictive versus liberal strategy</span><span class="headingEndMark"> — </span>For most patients, a restrictive transfusion strategy (ie, giving less blood, transfusing at a lower Hgb level, and aiming for a lower target Hgb level) is sufficient rather than a liberal transfusion strategy (ie, giving more blood, transfusing at a higher Hgb level). </p><p>For hemodynamically stable hospitalized pediatric patients, including hemodynamically stable children with critical illness, we recommend a restrictive RBC transfusion strategy (ie, Hgb of 7 g/dL as the transfusion threshold) rather than more liberal transfusion strategies. The available clinical trial data suggest that using restrictive transfusion thresholds reduces exposure to RBC transfusions without increasing mortality or serious morbidity [<a href="#rid7">7,8</a>].</p><p>Transfusion at higher Hgb levels may be appropriate in certain conditions such as acute blood loss from trauma or surgery, cyanotic congenital heart disease (CHD), malignancy, and chronic anemias (eg, sickle cell disease, thalassemia). (See <a class="local">'Specific clinical scenarios'</a> below.)</p><p class="headingAnchor" id="H4199029431"><span class="h2">Factors in clinical decision-making</span><span class="headingEndMark"> — </span>When making decisions about whether to transfuse, the following factors should be considered:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Degree of anemia (Hgb level)</strong> – In both children and adults, clinicians have sought a "transfusion trigger": an absolute Hgb value below which the patient needs RBC transfusion. However, clinicians should not use the Hgb alone as the sole basis for decision-making. Assigning an absolute level is difficult since the impact of a given degree of anemia varies with the clinical setting (eg, acute or chronic) and physiologic status of the patient. In addition, the physiologic response to anemia in children is different from adults. In children, dyspnea, impaired consciousness, and other symptoms of hemodynamic compromise may not appear until the Hgb is &lt;6 g/dL (hematocrit &lt;18 percent) if the anemia has developed slowly. In critically ill children who are stable (ie, not actively bleeding and without refractory shock or hypoxemia), an Hgb threshold of 7 g/dL (hematocrit of 21 percent) has been used to decrease transfusion requirements without increasing adverse outcomes [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1">The minimum Hgb concentration that can be tolerated without mortality or morbidity is not necessarily the optimum Hgb concentration to support growth and normal activities in children. Whatever the optimum value, actual RBC transfusion practice should be a balance between that value and the associated risks of transfusion. Complications of RBC transfusion are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5938.html" rel="external">"Red blood cell transfusion in infants and children: Administration and complications", section on 'Complications'</a>.)</p><p></p><p class="bulletIndent1">There are few studies of RBC transfusion requirements in children except in certain specific patient populations, such as children with sickle cell disease, critically ill children, premature neonates, and African children with severe anemia [<a href="#rid7">7,9-12</a>]. The available published guidelines regarding RBC transfusion in infants and children are based largely on observational data, a few clinical trials, and extrapolation of studies in adult patients [<a href="#rid13">13-16</a>].</p><p></p><p class="bulletIndent1">In general, RBC transfusion is warranted for severe anemia (Hgb levels &lt;5 to 6 g/dL or hematocrit &lt;15 to 18 percent) since the risk of mortality and other adverse outcomes is increased with this degree of anemia [<a href="#rid5">5,6</a>]. Transfusion is generally not indicated in children with Hgb concentrations &gt;10 g/dL (hematocrit &gt;30 percent). In patients with Hgb levels between 6 and 10 g/dL (hematocrit 18 to 30 percent), the decision to transfuse is dependent upon the clinical situation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acuity of anemia</strong> – Chronically anemic children often tolerate Hgb concentrations as low as 6 to 7 g/dL (hematocrit 18 to 21 percent) because they are able to maintain adequate intravascular volume and tissue oxygenation [<a href="#rid17">17</a>]. On the other hand, patients with an acute loss of blood and hypovolemia may require transfusion, depending on the extent of blood loss. (See <a class="local">'Chronic anemias'</a> below and <a class="local">'Trauma'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Degree of symptoms</strong> – Symptoms attributable to anemia can also impact the decision to transfuse. Most children have symptoms of anemia at Hgb levels &lt;6 or 7 g/dL (hematocrit &lt;18 to 21 percent) [<a href="#rid18">18</a>]. However, children with chronic anemia may not have symptoms at this level and children with acute blood loss and those with underlying medical conditions may develop symptoms at considerably higher Hgb levels. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiopulmonary stability</strong> – Transfusion is often warranted for anemia that is associated with hemodynamic instability, as discussed below. (See <a class="local">'Critical illness'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ongoing blood loss</strong> – For patients with blood loss from traumatic injuries or surgical blood loss, the decision to transfuse should consider whether there is ongoing blood loss. (See <a class="local">'Trauma'</a> below and <a class="local">'Surgery'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Underlying conditions</strong> – Higher target Hgb levels may be warranted in patients with underlying medical conditions that are associated with chronic anemia, such as sickle cell disease or leukemia. (See <a class="local">'Sickle cell disease'</a> below and <a class="local">'Malignancy'</a> below.)</p><p></p><p class="headingAnchor" id="H6"><span class="h1">SPECIFIC CLINICAL SCENARIOS</span><span class="headingEndMark"> — </span>The following is a brief review of common clinical scenarios in which pediatric patients may require RBC transfusions. Most of these conditions are discussed in detail elsewhere.</p><p class="headingAnchor" id="H1613163351"><span class="h2">Neonates</span><span class="headingEndMark"> — </span>Common reasons for RBC transfusion in neonates include hemolytic disease of the fetus and newborn, perinatal blood loss, anemia of prematurity, and iatrogenic withdrawal of blood for laboratory testing. (See  <a class="medical medical_review" href="/d/html/5933.html" rel="external">"Alloimmune hemolytic disease of the newborn: Postnatal diagnosis and management"</a> and  <a class="medical medical_review" href="/d/html/5385.html" rel="external">"Intrauterine fetal transfusion of red blood cells"</a> and  <a class="medical medical_review" href="/d/html/4962.html" rel="external">"Anemia of prematurity (AOP)"</a>.)</p><p>Thresholds for RBC transfusion in newborns are summarized in the table (<a class="graphic graphic_table graphicRef140490" href="/d/graphic/140490.html" rel="external">table 1</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate", section on 'Indications for transfusion'</a>.)</p><p class="headingAnchor" id="H3308648258"><span class="h2">Critical illness</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unstable</strong> – Transfusion is often warranted in unstable anemic pediatric patients who have cardiopulmonary compromise (ie, patients with unstable shock and/or severe hypoxemia). In this setting, the need for transfusion is usually determined by clinical parameters rather than the patient's Hgb level, though transfusion is rarely indicated if the Hgb level is &gt;10 g/dL (hematocrit &gt;30 percent) [<a href="#rid16">16,19</a>]. The minimum Hgb target for unstable critically ill patients who are not actively bleeding is uncertain. (See  <a class="medical medical_review" href="/d/html/86881.html" rel="external">"Septic shock in children in resource-abundant settings: Ongoing management after resuscitation", section on 'Blood transfusion'</a> and  <a class="medical medical_review" href="/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management", section on 'Fluid resuscitation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodynamically stable</strong> – The Pediatric Critical Care Blood Research Network (BloodNet) and the Pediatric Acute Lung Injury and Sepsis Investigators Network's consensus recommendations for RBC transfusion in critically ill children provide specific guidance for decision-making in a wide range of clinical scenarios [<a href="#rid16">16</a>]. We agree with the expert panel's recommendation that, for most critically ill children who are hemodynamically stable and not severely hypoxic, RBC transfusion <strong>not</strong> be given if the Hgb is ≥7 g/dL (hematocrit ≥21 percent). Exceptions to this include children with CHD, acute brain injury, sickle cell anemia, oncologic diseases, recent hematopoietic stem cell transplant, and acute blood loss due to trauma, in whom transfusion may be appropriate at a higher Hgb level, as discussed below. (See <a class="local">'Congenital heart disease surgery'</a> below and <a class="local">'Sickle cell disease'</a> below and <a class="local">'Malignancy'</a> below and <a class="local">'Trauma'</a> below.)</p><p></p><p class="bulletIndent1">A clinical trial randomly assigned 637 stabilized (ie, not hypotensive and not requiring escalating cardiovascular treatments) critically ill children to either a restrictive transfusion strategy (Hgb of 7 g/dL as the transfusion threshold) or a liberal strategy (Hgb of 9.5 g/dL as the transfusion threshold) [<a href="#rid7">7</a>]. The restrictive strategy decreased transfusion requirements without increasing adverse outcomes (ie, multiple organ dysfunction syndrome or death).</p><p></p><p class="headingAnchor" id="H2022003"><span class="h2">Trauma</span><span class="headingEndMark"> — </span>Trauma patients who present with hemodynamic instability often require RBC transfusion if they show little to no improvement with initial crystalloid infusions. (See  <a class="medical medical_review" href="/d/html/6571.html" rel="external">"Trauma management: Approach to the unstable child", section on 'Blood products'</a>.)</p><p>In patients who have profound hemorrhage or ongoing bleeding with an anticipated need to replace total blood volume, a massive transfusion protocol is generally appropriate since transfusion of RBC without platelets and plasma leads to dilutional coagulopathy and may worsen bleeding. (See  <a class="medical medical_review" href="/d/html/6571.html" rel="external">"Trauma management: Approach to the unstable child", section on 'Massive transfusion protocol'</a> and  <a class="medical medical_review" href="/d/html/7931.html" rel="external">"Massive blood transfusion"</a>.)</p><p class="headingAnchor" id="H2023865"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>For children with anemia who are undergoing surgery, management prior to surgery should include evaluation for the cause of anemia and, if warranted, initiation of appropriate treatment (eg, if iron deficiency is identified, iron therapy should be initiated). However, this approach may not be feasible in emergency or urgent procedures. (See  <a class="medical medical_review" href="/d/html/5927.html" rel="external">"Approach to the child with anemia"</a> and  <a class="medical medical_review" href="/d/html/15647.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Treatment"</a>.)</p><p>The decision to provide perioperative RBC transfusion should be individualized based upon the child's diagnosis, the surgical procedure, expected blood loss, and the degree of symptoms attributable to anemia:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with symptoms and/or large blood loss</strong> – For children with rapid bleeding, symptomatic anemia (eg, hypotension, tachycardia, or altered mental status), or evidence of tissue hypoxia (eg, lactic acidosis, ischemic changes on electrocardiogram), transfusion is often warranted regardless of the Hgb level. Intraoperative transfusion is generally required if blood loss exceeds 15 percent of blood volume. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Red blood cells'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic patients</strong> – In the setting of asymptomatic anemia, the American Society of Anesthesiologists recommends a restrictive perioperative RBC transfusion strategy (ie, transfusion threshold of Hgb &lt;8 g/dL); however, these guidelines excluded infants and children &lt;35 kg [<a href="#rid20">20</a>]. Children with certain underlying conditions, particularly sickle cell disease and cyanotic CHD, require higher Hgb levels to safely undergo general anesthesia. This issue is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Prophylactic preoperative transfusion'</a>.)</p><p></p><p>In children, surgeries that are often associated with high risk of blood loss requiring RBC transfusion include congenital heart disease (CHD) surgery, orthopedic surgery (particularly scoliosis surgery), certain plastic surgery procedures (eg, craniosynostosis repair), and certain surgical oncology procedures.</p><p>In adults, a variety of interventions have been undertaken to reduce surgical blood use. Many of these techniques can be used in older children without significant alteration of the adult protocols. Large-scale trials of these modalities in children have not been performed, although some reviews of experience are available [<a href="#rid21">21,22</a>]. Strategies used to reduce the need for RBC transfusion include preoperative management to increase Hgb levels and intraoperative interventions including cell salvage and antifibrinolytic agents [<a href="#rid23">23</a>]. These issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/94347.html" rel="external">"Perioperative blood management: Strategies to minimize transfusions"</a> and  <a class="medical medical_review" href="/d/html/7937.html" rel="external">"Surgical blood conservation: Intraoperative blood salvage"</a>.)</p><p class="headingAnchor" id="H2432925046"><span class="h3">Congenital heart disease surgery</span><span class="headingEndMark"> — </span>RBC transfusions are frequently required during and following surgical repair or palliation of CHD; however, the optimal target Hgb following CHD surgery is uncertain [<a href="#rid16">16,19,24</a>]. There is limited evidence that a restrictive transfusion strategy (Hgb threshold of 9 g/dL for cyanotic and 7 g/dL for noncyanotic disease) may reduce transfusion-related risks without increasing other adverse outcomes (ie, lactic acidosis, multiorgan dysfunction syndrome, prolonged intensive care length of stay, or death) [<a href="#rid9">9,25-27</a>].</p><p>In a randomized trial involving 162 infants with CHD undergoing surgical repair or palliation, patients were randomly assigned to either a postoperative conservative strategy (RBC transfusion for Hgb &lt;7 g/dL for biventricular repairs or &lt;9 g/dL for palliative procedures <strong>plus</strong> a clinical indication) or liberal strategy (RBC transfusion for Hgb &lt;9.5 g/dL for biventricular repairs or &lt;12 g/dL for palliative procedures regardless of clinical indication) [<a href="#rid27">27</a>]. Fewer infants required postoperative RBC transfusion in the conservative group than in the liberal group (48 versus 80 percent). There were no differences in in-hospital mortality (7 versus 6 percent), need for extracorporeal membrane oxygenation support (3 versus 4 percent), or median hospital length of stay (13 days in both groups). In addition, peak serum lactate levels and arteriovenous oxygen difference were similar in the two groups. </p><p class="headingAnchor" id="H2042778527"><span class="h3">Orthopedic surgery</span><span class="headingEndMark"> — </span>Certain orthopedic surgeries are often associated with significant blood loss requiring RBC transfusion. This is particularly true of spinal fusion surgery for scoliosis, which can be associated with massive blood loss. The severity of blood loss correlates with the number of osteotomies performed and spinal levels fused [<a href="#rid28">28</a>]. Several techniques have been used to reduce the transfusion rates in pediatric and adult patients undergoing spinal fusion. These include intraoperative blood salvage and antifibrinolytics (eg, <a class="drug drug_pediatric" data-topicid="12854" href="/d/drug information/12854.html" rel="external">tranexamic acid</a> and epsilon-aminocaproic acid) [<a href="#rid23">23</a>]. Other techniques were used in the past (eg, preoperative autologous blood donation, normovolemic hemodilution, intraoperative controlled hypotension), but these have fallen out of favor in the modern era [<a href="#rid29">29</a>]. These issues are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/91785.html" rel="external">"Anesthesia for elective spine surgery in adults", section on 'Blood loss during spinal surgery'</a> and  <a class="medical medical_review" href="/d/html/7930.html" rel="external">"Surgical blood conservation: Preoperative autologous blood donation"</a> and  <a class="medical medical_review" href="/d/html/7936.html" rel="external">"Surgical blood conservation: Acute normovolemic hemodilution"</a>.)</p><p class="headingAnchor" id="H161824705"><span class="h3">Other surgeries</span><span class="headingEndMark"> — </span>Other surgeries that occasionally require multiple units of RBCs include certain plastic surgery and surgical oncology procedures. In particular, surgical correction of craniosynostosis almost always requires RBC transfusion [<a href="#rid30">30</a>]. Measures that have reduced RBC allogeneic transfusions include the preoperative use of erythropoietin [<a href="#rid31">31</a>] and perioperative blood salvage [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/2910.html" rel="external">"Overview of craniosynostosis"</a> and  <a class="medical medical_review" href="/d/html/94347.html" rel="external">"Perioperative blood management: Strategies to minimize transfusions"</a>.)</p><p class="headingAnchor" id="H2024523"><span class="h2">Malignancy</span><span class="headingEndMark"> — </span>Children with cancer who are undergoing either cytotoxic chemotherapy or hematopoietic stem cell transplantation represent one of the largest groups of patients requiring frequent RBC transfusion.</p><p>Practice varies regarding RBC transfusion thresholds in pediatric cancer patients. One approach is to transfuse at an Hgb level of 6 to 7 g/dL (hematocrit 18 to 21 percent), which, as noted above, is the level at which most children become symptomatic [<a href="#rid33">33</a>]. (See <a class="local">'Factors in clinical decision-making'</a> above.)</p><p>Alternatively, some experts suggest an RBC transfusion threshold of Hgb level &lt;8 g/dL (hematocrit &lt;24 percent) to avoid the development of symptoms, particularly if ongoing chemotherapy-associated marrow suppression is likely [<a href="#rid16">16,34</a>]. Transfusion may also be warranted at higher Hgb levels if there are symptoms attributable to anemia. </p><p>Among pediatric patients undergoing hematopoietic stem cell transplant, observational data suggest that a restrictive transfusion strategy may reduce transfusion requirements without increasing adverse outcomes [<a href="#rid35">35</a>]. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/3538.html" rel="external">"Hematopoietic support after hematopoietic cell transplantation", section on 'Transfusion support'</a>.)</p><p class="headingAnchor" id="H4204270162"><span class="h2">Chronic kidney disease</span><span class="headingEndMark"> — </span>Anemia in children with chronic kidney disease is usually managed with iron supplementation and erythropoiesis-stimulating agents; RBC transfusion is <strong>not</strong> necessary for most patients. Management of anemia in chronic kidney disease is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Anemia'</a>.)</p><p class="headingAnchor" id="H4109060016"><span class="h2">Chronic anemias</span></p><p class="headingAnchor" id="H8"><span class="h3">Sickle cell disease</span><span class="headingEndMark"> — </span>Children with sickle cell disease commonly are transfused for the following indications (see  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Indications for transfusion'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Acute chest syndrome (see  <a class="medical medical_review" href="/d/html/16353.html" rel="external">"Acute chest syndrome (ACS) in sickle cell disease (adults and children)", section on 'Transfusion'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute stroke and primary and secondary stroke prevention (see  <a class="medical medical_review" href="/d/html/5926.html" rel="external">"Acute stroke (ischemic and hemorrhagic) in children and adults with sickle cell disease", section on 'TIA and ischemic stroke management'</a> and  <a class="medical medical_review" href="/d/html/106228.html" rel="external">"Prevention of stroke (initial or recurrent) in sickle cell disease", section on 'Prevention of a first ischemic stroke (primary stroke prophylaxis)'</a> and  <a class="medical medical_review" href="/d/html/106228.html" rel="external">"Prevention of stroke (initial or recurrent) in sickle cell disease", section on 'Prevention of recurrent ischemic stroke (secondary stroke prophylaxis)'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aplastic crisis and splenic sequestration crisis (see  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Symptomatic or severe anemia'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of recurrent priapism (see  <a class="medical medical_review" href="/d/html/7143.html" rel="external">"Priapism and erectile dysfunction in sickle cell disease", section on 'Regular red blood cell transfusions'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduction of perioperative complications using preoperative transfusion (see  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Prophylactic preoperative transfusion'</a>)</p><p></p><p>Transfusion in many of these conditions serves not only to increase oxygen delivery, but also to reduce vaso-occlusion by decreasing the percentage of sickle Hgb. Details of transfusion techniques, complications, and use of simple versus exchange transfusions are discussed separately. (See  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Thalassemia</span><span class="headingEndMark"> — </span>Thalassemia refers to a spectrum of diseases characterized by the absence or reduction of one or more globin chains in the Hgb molecule. RBC transfusion requirements vary among the different types of thalassemia as follows (<a class="graphic graphic_algorithm graphicRef127604" href="/d/graphic/127604.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta thalassemia major</strong> – Patients with beta thalassemia major (also called transfusion-dependent thalassemia) are typically managed with chronic transfusions and iron chelation therapy. (See  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia", section on 'Management of anemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thalassemia intermedia</strong> – Children and adolescents with thalassemia intermedia may require transfusions during periods of erythropoietic stress such as acute infectious illnesses, periods of rapid growth, or surgery. Some patients may require chronic transfusion therapy as they reach adulthood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thalassemia minor</strong> – Transfusions are not required, since anemia is very mild or absent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha thalassemia</strong> – Survival of infants with severe degrees of alpha thalassemia (eg, hemoglobin Barts) has improved following the introduction of intrauterine or early postnatal transfusion, but continued chronic transfusion is required [<a href="#rid36">36</a>]. Patients with hemoglobin H disease typically do not need transfusion in the first decade of life. (See  <a class="medical medical_review" href="/d/html/7090.html" rel="external">"Pathophysiology of thalassemia", section on 'Terminology and disease classification'</a> and  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Epidemiology'</a>.)</p><p></p><p>Management of the different types of thalassemia, including use of RBC transfusion, is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia", section on 'Management of anemia'</a>.)</p><p class="headingAnchor" id="H583275970"><span class="h3">Autoimmune hemolytic anemia</span><span class="headingEndMark"> — </span>Children with autoimmune hemolytic anemia (AIHA) may require RBC transfusion if the anemia is severe. Finding compatible RBC units to transfuse into a child with AIHA can be difficult and requires coordination with blood bank personnel. Transfusion can lead to additional hemolysis in patients with AIHA. However, it must be emphasized that <strong>transfusion therapy should not be withheld from a patient with life-threatening anemia</strong>. The patient's Hgb may not increase as expected due to hemolysis of transfused RBCs. Transfusion in patients with AIHA is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/107301.html" rel="external">"Autoimmune hemolytic anemia (AIHA) in children: Treatment and outcome", section on 'Severe or life-threatening anemia'</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Hypoproliferative anemia</span><span class="headingEndMark"> — </span>Other chronic anemias that require RBC transfusion in children and infants include hypoproliferative anemias, such as Diamond-Blackfan anemia and aplastic anemia. (See  <a class="medical medical_review" href="/d/html/131283.html" rel="external">"Diamond-Blackfan anemia", section on 'Transfusion therapy'</a> and  <a class="medical medical_review" href="/d/html/5923.html" rel="external">"Treatment of acquired aplastic anemia in children and adolescents"</a>.)</p><p class="headingAnchor" id="H3749744247"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120167.html" rel="external">"Society guideline links: Transfusion and patient blood management"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weighing the benefits and risks</strong> – Transfusion of red blood cells (RBCs) can be lifesaving in patients with severe blood loss or severe chronic anemia. However, RBC transfusions have risks, including transfusion-associated circulatory overload, transfusion-related acute lung injury, transmission of infectious agents, fever, hives, and various immunologic consequences (including graft-versus-host disease). As a result, the benefits of transfusion must be carefully weighed against the potential adverse effects of the intervention. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/d/html/5938.html" rel="external">"Red blood cell transfusion in infants and children: Administration and complications", section on 'Complications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General indications</strong> – When deciding whether to transfuse, clinicians should not use the hemoglobin (Hgb) alone as the sole basis for decision-making. Other factors to consider include the acuity of anemia, degree of symptoms, hemodynamic stability, and the presence and nature of underlying conditions. (See <a class="local">'Factors in clinical decision-making'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neonates</strong> – In neonates, common reasons for RBC transfusion include hemolytic disease of the fetus and newborn, perinatal blood loss, anemia of prematurity, and iatrogenic withdrawal of blood for laboratory testing. These issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unstable patients</strong> – Transfusion is often required for unstable anemic pediatric patients who have cardiopulmonary compromise (ie, patients with unstable shock and/or severe hypoxemia). In this setting, the need for transfusion is determined by clinical parameters rather than the patient's Hgb level, though transfusion is rarely indicated if the Hgb is &gt;10 g/dL. (See  <a class="medical medical_review" href="/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management", section on 'Fluid resuscitation'</a> and  <a class="medical medical_review" href="/d/html/86881.html" rel="external">"Septic shock in children in resource-abundant settings: Ongoing management after resuscitation", section on 'Blood transfusion'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stable patients</strong> – For most hemodynamically stable hospitalized pediatric patients, including hemodynamically stable children with critical illness, we recommend a restrictive RBC transfusion strategy (ie, Hgb of 7 g/dL as the transfusion threshold) rather than more liberal strategies (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Exceptions to this include the six conditions listed below. (See <a class="local">'Restrictive versus liberal strategy'</a> above and <a class="local">'Critical illness'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special circumstances</strong> – Separate criteria for transfusion may be used in the management of pediatric patients with the following conditions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Trauma, if there is ongoing active bleeding (see  <a class="medical medical_review" href="/d/html/6571.html" rel="external">"Trauma management: Approach to the unstable child", section on 'Blood products'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgery (see <a class="local">'Surgery'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Malignancy (see <a class="local">'Malignancy'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cyanotic congenital heart disease (see <a class="local">'Congenital heart disease surgery'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic kidney disease (see  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Anemia'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic anemias, including (see <a class="local">'Chronic anemias'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Sickle cell disease (see  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Indications for transfusion'</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Thalassemia (see  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia", section on 'Management of anemia'</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Autoimmune hemolytic anemia (see  <a class="medical medical_review" href="/d/html/107301.html" rel="external">"Autoimmune hemolytic anemia (AIHA) in children: Treatment and outcome", section on 'Severe or life-threatening anemia'</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Certain hypoproliferative anemias (eg, aplastic anemia, Diamond-Blackfan anemia, bone marrow failure syndromes) (see  <a class="medical medical_review" href="/d/html/5923.html" rel="external">"Treatment of acquired aplastic anemia in children and adolescents", section on 'Supportive care'</a> and  <a class="medical medical_review" href="/d/html/131283.html" rel="external">"Diamond-Blackfan anemia", section on 'Transfusion therapy'</a>)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Goel R, Chappidi MR, Patel EU, et al. Trends in Red Blood Cell, Plasma, and Platelet Transfusions in the United States, 1993-2014. JAMA 2018; 319:825.</a></li><li><a class="nounderline abstract_t">Goel R, Josephson CD, Patel EU, et al. Individual- and hospital-level correlates of red blood cell, platelet, and plasma transfusions among hospitalized children and neonates: a nationally representative study in the United States. Transfusion 2020; 60:1700.</a></li><li><a class="nounderline abstract_t">CASE RB, BERGLUND E, SARNOFF SJ. Ventricular function. VII. Changes in coronary resistance and ventricular function resulting from acutely induced anemia and the effect thereon of coronary stenosis. Am J Med 1955; 18:397.</a></li><li><a class="nounderline abstract_t">Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033.</a></li><li><a class="nounderline abstract_t">Doctor A, Cholette JM, Remy KE, et al. Recommendations on RBC Transfusion in General Critically Ill Children Based on Hemoglobin and/or Physiologic Thresholds From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative. Pediatr Crit Care Med 2018; 19:S98.</a></li><li><a class="nounderline abstract_t">Lackritz EM, Hightower AW, Zucker JR, et al. Longitudinal evaluation of severely anemic children in Kenya: the effect of transfusion on mortality and hematologic recovery. AIDS 1997; 11:1487.</a></li><li><a class="nounderline abstract_t">Lacroix J, Hébert PC, Hutchison JS, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med 2007; 356:1609.</a></li><li><a class="nounderline abstract_t">Carson JL, Stanworth SJ, Dennis JA, et al. Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database Syst Rev 2021; 12:CD002042.</a></li><li><a class="nounderline abstract_t">Willems A, Harrington K, Lacroix J, et al. Comparison of two red-cell transfusion strategies after pediatric cardiac surgery: a subgroup analysis. Crit Care Med 2010; 38:649.</a></li><li><a class="nounderline abstract_t">Estcourt LJ, Fortin PM, Trivella M, Hopewell S. Preoperative blood transfusions for sickle cell disease. Cochrane Database Syst Rev 2016; 4:CD003149.</a></li><li><a class="nounderline abstract_t">Whyte R, Kirpalani H. Low versus high haemoglobin concentration threshold for blood transfusion for preventing morbidity and mortality in very low birth weight infants. Cochrane Database Syst Rev 2011; :CD000512.</a></li><li><a class="nounderline abstract_t">Maitland K, Kiguli S, Olupot-Olupot P, et al. Immediate Transfusion in African Children with Uncomplicated Severe Anemia. N Engl J Med 2019; 381:407.</a></li><li><a class="nounderline abstract_t">Roseff SD, Luban NL, Manno CS. Guidelines for assessing appropriateness of pediatric transfusion. Transfusion 2002; 42:1398.</a></li><li><a class="nounderline abstract_t">Gibson BE, Todd A, Roberts I, et al. Transfusion guidelines for neonates and older children. Br J Haematol 2004; 124:433.</a></li><li><a class="nounderline abstract_t">Padhi S, Kemmis-Betty S, Rajesh S, et al. Blood transfusion: summary of NICE guidance. BMJ 2015; 351:h5832.</a></li><li><a class="nounderline abstract_t">Valentine SL, Bembea MM, Muszynski JA, et al. Consensus Recommendations for RBC Transfusion Practice in Critically Ill Children From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative. Pediatr Crit Care Med 2018; 19:884.</a></li><li class="breakAll">National Heart, Lung, and Blood Institute, Evidence-based management of sickle cell disease: Expert panel report, 2014. Available at: https://www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease (Accessed on October 11, 2018).</li><li class="breakAll">Brugnara C, Oski FA, Nathan DG. Diagnostic approach to the anemic patient. In: Nathan and Oski's Hematology and Oncology of Infancy and Childhood, 8th ed, Orkin SH, Fisher DE, Look T, Lux SE, Ginsburg D, Nathan DG, et AL (Eds), WB Saunders, Philadelphia 2015. p.293.</li><li><a class="nounderline abstract_t">Lacroix J, Demaret P, Tucci M. Red blood cell transfusion: decision making in pediatric intensive care units. Semin Perinatol 2012; 36:225.</a></li><li><a class="nounderline abstract_t">American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*. Anesthesiology 2015; 122:241.</a></li><li><a class="nounderline abstract_t">Williams GD, Bratton SL, Ramamoorthy C. Factors associated with blood loss and blood product transfusions: a multivariate analysis in children after open-heart surgery. Anesth Analg 1999; 89:57.</a></li><li><a class="nounderline abstract_t">Kwiatkowski JL, Manno CS. Blood transfusion support in pediatric cardiovascular surgery. Transfus Sci 1999; 21:63.</a></li><li><a class="nounderline abstract_t">Goel R, Cushing MM, Tobian AA. Pediatric Patient Blood Management Programs: Not Just Transfusing Little Adults. Transfus Med Rev 2016; 30:235.</a></li><li><a class="nounderline abstract_t">Mazine A, Rached-D'Astous S, Ducruet T, et al. Blood Transfusions After Pediatric Cardiac Operations: A North American Multicenter Prospective Study. Ann Thorac Surg 2015; 100:671.</a></li><li><a class="nounderline abstract_t">Wilkinson KL, Brunskill SJ, Doree C, et al. Red cell transfusion management for patients undergoing cardiac surgery for congenital heart disease. Cochrane Database Syst Rev 2014; :CD009752.</a></li><li><a class="nounderline abstract_t">Cholette JM, Rubenstein JS, Alfieris GM, et al. Children with single-ventricle physiology do not benefit from higher hemoglobin levels post cavopulmonary connection: results of a prospective, randomized, controlled trial of a restrictive versus liberal red-cell transfusion strategy. Pediatr Crit Care Med 2011; 12:39.</a></li><li><a class="nounderline abstract_t">Cholette JM, Swartz MF, Rubenstein J, et al. Outcomes Using a Conservative Versus Liberal Red Blood Cell Transfusion Strategy in Infants Requiring Cardiac Operation. Ann Thorac Surg 2017; 103:206.</a></li><li><a class="nounderline abstract_t">Koerner JD, Patel A, Zhao C, et al. Blood loss during posterior spinal fusion for adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 2014; 39:1479.</a></li><li class="breakAll">National Advisory Committee on Blood and Blood Products. NAC Statement on Perioperative Autologous Blood Donation (2018). Available at: https://nacblood.ca/en/resource/nac-statement-perioperative-autologous-blood-donation (Accessed on September 14, 2018).</li><li><a class="nounderline abstract_t">Faberowski LW, Black S, Mickle JP. Blood loss and transfusion practice in the perioperative management of craniosynostosis repair. J Neurosurg Anesthesiol 1999; 11:167.</a></li><li><a class="nounderline abstract_t">Fearon JA, Weinthal J. The use of recombinant erythropoietin in the reduction of blood transfusion rates in craniosynostosis repair in infants and children. Plast Reconstr Surg 2002; 109:2190.</a></li><li><a class="nounderline abstract_t">Dahmani S, Orliaguet GA, Meyer PG, et al. Perioperative blood salvage during surgical correction of craniosynostosis in infants. Br J Anaesth 2000; 85:550.</a></li><li class="breakAll">Agarwal AK, Hastings CA, and Feusner J. Hematologic supportive care for children with cancer. In: Principles and Practice of Pediatric Oncology, 6, Pizzo PA, Poplack DG (Eds), Lippincott Williams and Wilkins, Philadelphia 2011. p.1152.</li><li><a class="nounderline abstract_t">Roubinian N, Carson JL. Red Blood Cell Transfusion Strategies in Adult and Pediatric Patients with Malignancy. Hematol Oncol Clin North Am 2016; 30:529.</a></li><li><a class="nounderline abstract_t">Lightdale JR, Randolph AG, Tran CM, et al. Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18:813.</a></li><li><a class="nounderline abstract_t">Singer ST, Styles L, Bojanowski J, et al. Changing outcome of homozygous alpha-thalassemia: cautious optimism. J Pediatr Hematol Oncol 2000; 22:539.</a></li></ol></div><div id="topicVersionRevision">Topic 5910 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29486023" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Trends in Red Blood Cell, Plasma, and Platelet Transfusions in the United States, 1993-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32589286" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Individual- and hospital-level correlates of red blood cell, platelet, and plasma transfusions among hospitalized children and neonates: a nationally representative study in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14349964" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Ventricular function. VII. Changes in coronary resistance and ventricular function resulting from acutely induced anemia and the effect thereon of coronary stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25203083" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30161064" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Recommendations on RBC Transfusion in General Critically Ill Children Based on Hemoglobin and/or Physiologic Thresholds From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9342071" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Longitudinal evaluation of severely anemic children in Kenya: the effect of transfusion on mortality and hematologic recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17442904" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Transfusion strategies for patients in pediatric intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34932836" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Transfusion thresholds for guiding red blood cell transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19789443" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparison of two red-cell transfusion strategies after pediatric cardiac surgery: a subgroup analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27049331" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Preoperative blood transfusions for sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22071798" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Low versus high haemoglobin concentration threshold for blood transfusion for preventing morbidity and mortality in very low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31365799" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Immediate Transfusion in African Children with Uncomplicated Severe Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12421212" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Guidelines for assessing appropriateness of pediatric transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14984493" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Transfusion guidelines for neonates and older children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26581483" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Blood transfusion: summary of NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30180125" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Consensus Recommendations for RBC Transfusion Practice in Critically Ill Children From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30180125" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Consensus Recommendations for RBC Transfusion Practice in Critically Ill Children From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30180125" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Consensus Recommendations for RBC Transfusion Practice in Critically Ill Children From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22818542" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Red blood cell transfusion: decision making in pediatric intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25545654" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10389779" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Factors associated with blood loss and blood product transfusions: a multivariate analysis in children after open-heart surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10724785" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Blood transfusion support in pediatric cardiovascular surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27559005" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pediatric Patient Blood Management Programs: Not Just Transfusing Little Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26141778" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Blood Transfusions After Pediatric Cardiac Operations: A North American Multicenter Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24510598" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Red cell transfusion management for patients undergoing cardiac surgery for congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20495502" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Children with single-ventricle physiology do not benefit from higher hemoglobin levels post cavopulmonary connection: results of a prospective, randomized, controlled trial of a restrictive versus liberal red-cell transfusion strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27496630" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Outcomes Using a Conservative Versus Liberal Red Blood Cell Transfusion Strategy in Infants Requiring Cardiac Operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24859581" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Blood loss during posterior spinal fusion for adolescent idiopathic scoliosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24859581" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Blood loss during posterior spinal fusion for adolescent idiopathic scoliosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10414670" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Blood loss and transfusion practice in the perioperative management of craniosynostosis repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12045535" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The use of recombinant erythropoietin in the reduction of blood transfusion rates in craniosynostosis repair in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11064613" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Perioperative blood salvage during surgical correction of craniosynostosis in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11064613" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Perioperative blood salvage during surgical correction of craniosynostosis in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27112994" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Red Blood Cell Transfusion Strategies in Adult and Pediatric Patients with Malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22080050" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11132224" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Changing outcome of homozygous alpha-thalassemia: cautious optimism.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
